FDA inspection
Glaxo Wellcome S.A.: FDA inspection ending Jun 8, 2022
FDA inspection 1259789 · No Action Indicated (NAI) · Aranda De Duero
Key facts
| Inspection ID | 1259789 |
|---|---|
| Firm | Glaxo Wellcome S.A. |
| FEI number | 3004195227 |
| Address | Avenida De Extremadura 3 |
| City | Aranda De Duero |
| Country | Spain |
| Fiscal year | 2022 |
| Inspection end date | Jun 8, 2022 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data